tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Sheiner PA et al. Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506. 1994 Transplantation pmid:7513099
Gaweco AS et al. Distinct intragraft cytokine gene expression patterns during acute hepatic rejection under cyclosporine versus FK 506 primary immunosuppression. 1994 Transplant. Proc. pmid:7527948
Fruman DA et al. Immunophilins in protein folding and immunosuppression. 1994 FASEB J. pmid:7513288
Mathieu C et al. Potential role of 1,25(OH)2 vitamin D3 as a dose-reducing agent for cyclosporine and FK 506. 1994 Transplant. Proc. pmid:7527950
Piekoszewski W et al. Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. 1994 J. Pharmacol. Exp. Ther. pmid:7513355
Ueki M et al. Peritoneal-omental pouch as a site for islet allotransplantation. 1994 Transplant. Proc. pmid:7513462
Yasunami Y et al. Acceptance of donor-specific islet allografts in rat by intraportal preimmunization with islets and FK 506. 1994 Transplant. Proc. pmid:7513467
Ueki M et al. Functional and morphologic characterization of renal subcapsular islet isografts in rats treated with FK 506. 1994 Transplant. Proc. pmid:7513469
Yli-Kauhaluoma J and Janda KD Twisted alpha-keto amides as transition-state analogues for acyl-transfer reactions: synthesis of the immunoconjugates. 1994 Bioorg. Med. Chem. pmid:7528089
Stan R et al. Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue. 1994 J. Biol. Chem. pmid:7528205
Hachida M et al. [The rescue effect of FK506 in refractory rejection after cardiac transplantation]. 1994 Nihon Kyobu Geka Gakkai Zasshi pmid:7528255
Sugiyama E et al. FK506, an immunosuppressant, partially inhibits interleukin 6 production by adherent rheumatoid synovial cells. 1994 J. Rheumatol. pmid:7528280
Whiting PH Acute and chronic nephrotoxicity associated with immunosuppressive drugs. 1994 Curr. Opin. Nephrol. Hypertens. pmid:7531104
Lauerma AI and Maibach HI Topical FK506--clinical potential or laboratory curiosity? 1994 Dermatology (Basel) pmid:7514460
Chen TS et al. Microbial transformation of immunosuppressive compounds. IV. Hydroxylation and hemiketal formation of ascomycin (immunomycin) by Streptomyces sp. MA 6970 (ATCC No. 55281). 1994 J. Antibiot. pmid:7531195
Brillantes AB et al. Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. 1994 Cell pmid:7514503
Bennett WM et al. Nephrotoxicity of immunosuppressive drugs. 1994 Nephrol. Dial. Transplant. pmid:7528363
Bennett WM et al. Nephrotoxicity of immunosuppressive drugs. 1994 Miner Electrolyte Metab pmid:7531274
McCashland TM et al. Bile acid metabolism and biliary secretion in patients receiving orthotopic liver transplants: differing effects of cyclosporine and FK 506. 1994 Hepatology pmid:7514561
Husi H et al. Mapping of the immunophilin-immunosuppressant site of interaction on calcineurin. 1994 J. Biol. Chem. pmid:7514602
Moudgil A et al. Inhibition of in vitro immunoglobulin production by a novel immunosuppressive drug brequinar sodium. 1994 Transplant Sci pmid:7528627
Sekigawa I et al. FK506 can inhibit apoptotic cell death induced by the HIV-1 envelope glycoprotein gp120. 1994 AIDS pmid:7531458
Mazariegos GV et al. Rubella infection after orthotopic liver transplantation. 1994 Pediatr. Infect. Dis. J. pmid:7514783
Mañez R et al. Fluconazole therapy in transplant recipients receiving FK506. 1994 Transplantation pmid:7515201
Foster CA et al. Pharmacological modulation of endothelial cell-associated adhesion molecule expression: implications for future treatment of dermatological diseases. 1994 J. Dermatol. pmid:7531725
Furue M et al. Immunosuppressive effects of azelastine hydrochloride on contact hypersensitivity and T-cell proliferative response: a comparative study with FK-506. 1994 J. Invest. Dermatol. pmid:7517981
Suzuki S and Toledo-Pereyra LH Interleukin 1 and tumor necrosis factor production as the initial stimulants of liver ischemia and reperfusion injury. 1994 J. Surg. Res. pmid:7518017
Nishimori H et al. Combination therapy with FK 506 and splenectomy may induce tolerance in cardiac xenografts. 1994 Transplant. Proc. pmid:7518102
Kawauchi M et al. Cardiac xenotransplantation from pig to Japanese monkey with splenectomy, tacrolims, filtration plasmapheresis, and nafamstat mesilate. 1994 Transplant. Proc. pmid:7518105
Ohtsuka S et al. Effect of splenectomy on hamster-to-rat pancreas xenotransplantation. 1994 Transplant. Proc. pmid:7518109
Yasutomi M et al. Mechanism of antibody production in hamster-to-rat concordant xenotransplantation: establishment of a simple model using intravenous injection of concordant splenocytes. 1994 Transplant. Proc. pmid:7518110
Miyazawa H et al. Mechanisms of hamster kidney graft rejection in the rat. 1994 Transplant. Proc. pmid:7518111
Nardo B et al. Pretransplant xenogeneic blood transfusion combined with FK 506 prolongs hamster-to-rat liver xenograft survival. 1994 Transplant. Proc. pmid:7518112
Duncan JI Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporin A, FK-506, and rapamycin. 1994 J. Invest. Dermatol. pmid:7507155
Reding R et al. Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Efficacy, toxicity, and dose regimen in 23 children. 1994 Transplantation pmid:7507272
Zuany-Amorim C et al. Modulation by rm interferon-gamma and CD4+ T-lymphocytes of allergic eosinophil accumulation in the mice peritoneal cavity. 1994 Ann. N. Y. Acad. Sci. pmid:7518212
Helekar SA et al. Prolyl isomerase requirement for the expression of functional homo-oligomeric ligand-gated ion channels. 1994 Neuron pmid:7507339
Sabatini DM et al. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. 1994 Cell pmid:7518356
Parsons JN et al. Regulation of calcineurin phosphatase activity and interaction with the FK-506.FK-506 binding protein complex. 1994 J. Biol. Chem. pmid:7518461
Cunningham KW and Fink GR Calcineurin-dependent growth control in Saccharomyces cerevisiae mutants lacking PMC1, a homolog of plasma membrane Ca2+ ATPases. 1994 J. Cell Biol. pmid:7507493
Wang T et al. Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12. 1994 Science pmid:7518616
Fealy MJ et al. Efficacy of rapamycin and FK 506 in prolonging rat hind limb allograft survival. 1994 Ann. Surg. pmid:7507657
Tanabe M et al. Combined immunosuppressive therapy with low dose FK506 and antimetabolites in rat allogeneic heart transplantation. 1994 Transplantation pmid:7518619
Bossard MJ et al. Catalytic and ligand binding properties of the FK506 binding protein FKBP12: effects of the single amino acid substitution of Tyr82 to Leu. 1994 Biochem. J. pmid:7507662
Tamura K et al. Interaction of tacrolimus(FK506) and its metabolites with FKBP and calcineurin. 1994 Biochem. Biophys. Res. Commun. pmid:7518678
Hooks MA Tacrolimus, a new immunosuppressant--a review of the literature. 1994 Ann Pharmacother pmid:7518710
Frizell E et al. FK506 enhances fibrogenesis in in vitro and in vivo models of liver fibrosis in rats. 1994 Gastroenterology pmid:7518783
Kitamura M et al. Clinical experience of FK 506 for renal allograft transplantation. 1994 Transplant. Proc. pmid:7520611
Chen CL et al. FK 506 used as rescue therapy for refractory liver allograft rejection. 1994 Transplant. Proc. pmid:7520612
Nakata S et al. Immunosuppressive mechanisms of deoxymethylspergualin and FK 506 on in vitro cytotoxic T lymphocytes. 1994 Transplant. Proc. pmid:7520613
Morphopathological findings of renal allografts under FK 506 therapy. Japanese FK 506 Study Group. 1994 Transplant. Proc. pmid:7520614
Imanishi M et al. Induction of tolerance by intrathymic injection of donor bone marrow cells in the rat: simultaneous heart and skin allograft model. 1994 Transplant. Proc. pmid:7520615
Charters AR et al. Immunochemical analysis of FK506 binding proteins in neuronal cell lines and rat brain. 1994 Biochem. Soc. Trans. pmid:7535258
Matsuura T et al. Organ-specific tolerance induced by intrathymic injection of donor bone marrow cells and FK 506 or antilymphocyte serum in rat heart transplantation. 1994 Transplant. Proc. pmid:7520616
Charters AR et al. The subcellular distribution of FK506 binding proteins in rat brain. 1994 Biochem. Soc. Trans. pmid:7535259
Ota K Living donor kidney transplantation in Japan. 1994 Transplant. Proc. pmid:7520622
Hirose M and Kuroda Y Reinforcement of cyclosporin A-induced red cell destruction by superoxide. 1994 Tokushima J. Exp. Med. pmid:7535479
Takahara S et al. Monitoring of FK 506 blood levels in kidney transplant recipients. 1994 Transplant. Proc. pmid:7520623
Surdacka E et al. [New immunosuppressive drugs in transplantation]. 1994 Prz. Lek. pmid:7532870
Tai PK et al. Potentiation of progesterone receptor-mediated transcription by the immunosuppressant FK506. 1994 Biochemistry pmid:7521210
Akita K et al. Suppression of nitric oxide production by cyclosporin A and FK506A in rat vascular smooth muscle cells. 1994 Clin. Exp. Pharmacol. Physiol. pmid:7521274
Woo J et al. FK506 inhibits the differentiation of developing thymocytes but not negative selection of T cell receptor V beta 5+ and V beta 11+ T lymphocytes in vivo. 1994 Transpl. Immunol. pmid:7521743
Kasiske BL The effects of immunosuppressive agents on plasma lipoproteins after organ transplantation. 1994 J. Lab. Clin. Med. pmid:7521894
Clipstone NA et al. Molecular analysis of the interaction of calcineurin with drug-immunophilin complexes. 1994 J. Biol. Chem. pmid:7523407
Lemster B et al. Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial. 1994 Autoimmunity pmid:7539635
Karmann K et al. Endothelial cell-induced resistance to cyclosporin A in human peripheral blood T cells requires contact-dependent interactions involving CD2 but not CD28. 1994 J. Immunol. pmid:7523510
Wakabayashi H et al. The effect of FK506 on warm ischemia and reperfusion injury in the rat liver. 1994 Surg. Today pmid:7539646
Hiromura K et al. FK506 inhibits renal glomerular thrombosis induced in rats by nephrotoxic serum and lipopolysaccharide. 1994 Kidney Int. pmid:7523750
Ohtomo Y et al. Coexisting NPY and NE synergistically regulate renal tubular Na+, K(+)-ATPase activity. 1994 Kidney Int. pmid:7523751
Siekierka JJ Probing T-cell signal transduction pathways with the immunosuppressive drugs, FK-506 and rapamycin. 1994 Immunol. Res. pmid:7539823
Moore R and Lord R Tacrolimus (FK506) versus cyclosporin in prevention of liver allograft rejection. 1994 Lancet pmid:7523805
Krentz AJ et al. Tacrolimus (FK506) versus cyclosporin in prevention of liver allograft rejection. 1994 Lancet pmid:7523806
Collins RH Tacrolimus (FK506) versus cyclosporin in prevention of liver allograft rejection. 1994 Lancet pmid:7523807
Papaccio G et al. The immunosuppressant FK506 inhibits the damage to mouse pancreatic islets induced by low dose streptozocin. 1994 Cell Tissue Res. pmid:7525068
Robertus J Structure-based drug design ten years on. 1994 Nat. Struct. Biol. pmid:7545074
Milan D et al. The latch region of calcineurin B is involved in both immunosuppressant-immunophilin complex docking and phosphatase activation. 1994 Cell pmid:7525078
Tamir H et al. Secretogogue-induced gating of chloride channels in the secretory vesicles of parafollicular cells. 1994 Endocrinology pmid:7525261
Shafiee A et al. Enzymology of FK-506 biosynthesis. Purification and characterization of 31-O-desmethylFK-506 O:methyltransferase from Streptomyces sp. MA6858. 1994 Eur. J. Biochem. pmid:7525282
Benton BM et al. A novel FK506- and rapamycin-binding protein (FPR3 gene product) in the yeast Saccharomyces cerevisiae is a proline rotamase localized to the nucleolus. 1994 J. Cell Biol. pmid:7525596
Gruber SA et al. Pharmacokinetics of FK506 after intravenous and oral administration in patients awaiting renal transplantation. 1994 J Clin Pharmacol pmid:7525661
Funk JO and Maibach HI Horizons in pharmacologic intervention in allergic contact dermatitis. 1994 J. Am. Acad. Dermatol. pmid:7525668
Mukaida N et al. Molecular mechanism of interleukin-8 gene expression. 1994 J. Leukoc. Biol. pmid:7525815
Matsunami H et al. New technique for measuring tacrolimus concentrations in blood. 1994 Am J Hosp Pharm pmid:7510929
Ericzon B et al. Glucose metabolism in liver transplant recipients treated with FK 506 or cyclosporin in the European multicentre study. 1994 Transpl. Int. pmid:11271178
Undre N and Möller A Pharmacokinetic interpretation of FK 506 levels in blood and in plasma during a European randomised study in primary liver transplant patients. The FK 506 European Study Group. 1994 Transpl. Int. pmid:11271189
Yano K et al. Effects of intrahepatic arterial and intraportal administration of FK 506 on liver allograft survival in rats. 1994 Transpl. Int. pmid:11271200
Devlin J et al. Renal complications and development of hypertension in the European study of FK 506 and cyclosporin in primary liver transplant recipients. 1994 Transpl. Int. pmid:11271207
Two-year follow-up study of the efficacy and safety of FK 506 in kidney transplant patients. Japanese FK 506 Study Group. 1994 Transpl. Int. pmid:11271216
Neuhaus P et al. Neurological complications in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation. 1994 Transpl. Int. pmid:11271222
Bismuth H et al. Focus on intractable rejection: 6-month results of the European multicentre liver study of FK 506 and cyclosporin A. 1994 Transpl. Int. pmid:11271231
McMaster P Patient and graft survival in the European Multicentre Liver Study--FK 506 vs cyclosporin A. 1994 Transpl. Int. pmid:11271239
Mueller AR et al. Neurotoxicity after orthotopic liver transplantation in cyclosporin A- and FK 506-treated patients. 1994 Transpl. Int. pmid:11271254
Stark JH et al. Sensitivity of baboon lymphocytes to cyclosporin A and FK 506: relative resistance of alloactivated cells to CyA. 1994 Transpl. Int. pmid:7527639
Abdalla AH et al. FK 506 as an alternative in cyclosporin-induced hemolytic uremic syndrome in a kidney transplant recipient. 1994 Transpl. Int. pmid:7527640
Cooper MH et al. Short-term myeloid reconstitution following TBI is not adversely affected by doses of FK506 that abrogate lethal GVHD. 1994 Bone Marrow Transplant. pmid:7527689
Lea JP et al. Evidence that the inhibition of Na+/K(+)-ATPase activity by FK506 involves calcineurin. 1994 Kidney Int. pmid:7527873
Yasunami Y and Ikeda S Induction of donor specific unresponsiveness in rat islet allografts by intraportal grafting and FK506. 1994 Cell Transplant pmid:7512877
Nielsen FT et al. Nephrotoxity of FK 506: a preliminary study on comparative aspects of FK 506 and cyclosporine nephrotoxicity. 1994 Transplant. Proc. pmid:7527946
Mor E et al. Reversal of gastrointestinal toxicity associated with long-term FK506 immunosuppression by conversion to cyclosporine in liver transplant recipients. 1994 Transplantation pmid:7513098
Fisher A et al. Gastrointestinal toxicity associated with FK 506 in liver transplant recipients. 1994 Transplant. Proc. pmid:7527947